Variable name;level;Overall;Yes;No;p;test
;n;1357;447;909;;
Age;[0 -40);801;407 (50.8);394 (49.2);<0.001;
;40+;554;40 (7.2);514 (92.8);;
Age (mean);;38.7 [34.9, 41.6];34.4 [31.2, 37.2];40.5 [37.6, 42.3];<0.001;nonnorm
Number of children;0;373;231 (62.1);141 (37.9);<0.001;
;1;279;99 (35.5);180 (64.5);;
;More than 1;705;117 (16.6);588 (83.4);;
BMI;<18.5;79;30 (38);49 (62);0.002;
;25-29.9;257;88 (34.4);168 (65.6);;
;>=30;107;20 (18.7);87 (81.3);;
;18.5-24.9;807;299 (37.1);508 (62.9);;
BMI (mean);;22.6 [20.5, 25.5];22.3 [20.3, 25.0];22.8 [20.7, 25.9];0.005;nonnorm
Treatment center;Curie Paris;818;287 (35.1);531 (64.9);NaN;
;Curie St Cloud;538;160 (29.7);378 (70.3);;
;Others;0;0 (NaN);0 (NaN);;
Genetic Analysis;No;656;131 (20);525 (80);<0.001;
;Yes;701;316 (45.1);384 (54.9);;
Hereditary predisposition;No;547;240 (44);306 (56);0.235;
;Yes;140;70 (50);70 (50);;
Inflammatory BC;No;1338;443 (33.1);895 (66.9);0.469;
;Yes;18;4 (22.2);14 (77.8);;
Clinical Tumor size (mm);;30.3 (21.7);31.5 (20.3);29.7 (22.4);0.148;
Clinical N stage (TNM);N0;854;281 (32.9);573 (67.1);0.859;
;N1-N2-N3;492;165 (33.5);327 (66.5);;
SBR grade;Grade I-II;586;166 (28.3);420 (71.7);0.002;
;Grade III;760;278 (36.6);482 (63.4);;
Histological type;NST;1265;426 (33.7);839 (66.3);0.014;
;Lobular;54;8 (14.8);46 (85.2);;
;Others;36;13 (36.1);23 (63.9);;
Neoajuvant chemotherapy;No;744;201 (27);543 (73);<0.001;
;Yes;612;246 (40.2);366 (59.8);;
Chemotherapy setting;NAC;611;245 (40.1);366 (59.9);NaN;
;Adjuvant;744;201 (27);543 (73);;
;NAC and adjuvant;0;0 (NaN);0 (NaN);;
;Chemotherapy without surgery;1;1 (100);0 (0);;
;No;0;0 (NaN);0 (NaN);;
